NCT00495924View on ClinicalTrials.gov

Perioperative Cancer Cell Dissemination and Systemic Immune Suppression in Resectable Ductal Pancreatic Adenocarcinoma

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

October 31, 2006

Study Completion Date

October 31, 2008

Conditions
Pancreatic NeoplasmsAdenocarcinomaNeoplasm Circulating CellsTumor Markers, BiologicalMonitoring, Immunologic
Interventions
PROCEDURE

Pancreatic resection (PD)

PD is a standard therapeutic surgical procedure. No additional interventions are performed.

Trial Locations (1)

B-3060

Department of Abdominal Surgery, Catholic University Leuven, Leuven

All Listed Sponsors
collaborator

Research Foundation Flanders

OTHER

collaborator

Agentschap voor Innovatie door Wetenschap en Technologie

OTHER

lead

KU Leuven

OTHER

NCT00495924 - Perioperative Cancer Cell Dissemination and Systemic Immune Suppression in Resectable Ductal Pancreatic Adenocarcinoma | Biotech Hunter | Biotech Hunter